A Study of Duloxetine (LY248686) in Japanese Children and Adolescents With Depressive Disorder

• Status: Completed
• Trial end date: 2019-11-08
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the efficacy of duloxetine hydrochloride versus placebo in the treatment of Japanese children and adolescents with depressive disorder.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company; Shionogi
• Collaborators: Eli Lilly and Company; Shionogi
• Treatments: Duloxetine Hydrochloride

Criteria

Inclusion Criteria:

• Participants diagnosed with Major Depressive Disorder or persistent depressive disorder and completely meet the criteria of major depressive episode as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) with the Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-KID) ver.7.0.2.

• Participants whose incipient age of depression was ≥7 years old.

• Total score of CDRS-R is ≥40 and CGI-S score is ≥4 at both screening and baseline.

Exclusion Criteria:

• Have remarkable response to psycho-education (defined as >30% decrease in the total score of CDRS-R between screening and baseline).

• Have a current or previous diagnosis (DSM-5) of the following as judged by the investigator:

• Neurodevelopmental disorders

• Schizophrenia spectrum and other psychotic disorders

• Bipolar and related disorders

• Trauma and stressor-related disorders

• Disruptive · Impulse Control · and Conduct disorders

• Have a current diagnosis (DSM-5) of the following as judged by the investigator:

• Obsessive-compulsive and related disorders

• Anorexia nervosa, Bulimia nervosa, Binge-eating disorder

• Sleep-wake disorders

• Neurocognitive disorders

• Disruptive mood dysregulation disorder

• Have personality disorders, in the judgement of the investigator.